Search

AB Science SA

Atidarymo kaina

1.144 -1.21

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.138

Max

1.172

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-3.4M

Pardavimai

512K

Pelno marža

-656.641

Darbuotojai

36

EBITDA

-1.9M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+327.13% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

79M

Ankstesnė atidarymo kaina

2.35

Ankstesnė uždarymo kaina

1.144

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-29 23:28; UTC

Karštos akcijos

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

2025-10-29 23:07; UTC

Uždarbis

Prudential PLC 3Q New Business Profit Up 13%

2025-10-30 00:00; UTC

Uždarbis

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

2025-10-30 00:00; UTC

Uždarbis

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

2025-10-30 00:00; UTC

Uždarbis

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

2025-10-29 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

2025-10-29 23:40; UTC

Uždarbis

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

2025-10-29 23:38; UTC

Rinkos pokalbiai

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

2025-10-29 23:25; UTC

Uždarbis

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

2025-10-29 22:51; UTC

Uždarbis

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

2025-10-29 22:45; UTC

Uždarbis

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

2025-10-29 22:41; UTC

Uždarbis

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

2025-10-29 22:41; UTC

Uždarbis

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

2025-10-29 22:09; UTC

Uždarbis

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

2025-10-29 22:08; UTC

Rinkos pokalbiai
Uždarbis

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

2025-10-29 21:58; UTC

Uždarbis

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

2025-10-29 21:58; UTC

Uždarbis

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

2025-10-29 21:57; UTC

Uždarbis

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

2025-10-29 21:54; UTC

Uždarbis

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

2025-10-29 21:46; UTC

Uždarbis

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

2025-10-29 21:43; UTC

Uždarbis

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

2025-10-29 21:43; UTC

Uždarbis

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

2025-10-29 21:42; UTC

Uždarbis

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

2025-10-29 21:42; UTC

Uždarbis

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

2025-10-29 21:41; UTC

Uždarbis

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

2025-10-29 21:41; UTC

Uždarbis

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

2025-10-29 21:41; UTC

Uždarbis

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

2025-10-29 21:41; UTC

Uždarbis

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

2025-10-29 21:40; UTC

Uždarbis

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

2025-10-29 21:39; UTC

Uždarbis

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

AB Science SA Prognozė

Kainos tikslas

By TipRanks

327.13% į viršų

12 mėnesių prognozė

Vidutinis 4.997 EUR  327.13%

Aukščiausias 5 EUR

Žemiausias 5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AB Science SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
help-icon Live chat